

TABLE 2
Parameters

Parameter	Value	Units	Source
k_{on}	4.80	$nM^{-1}h^{-1}$	Maass [9] Nessler [1] Jin [7] Datta-Mannan [3]
k_{off}	2.00	h^{-1}	Tsumura [12] Maass [9] Nessler [1] Jin [7] Datta-Mannan [3]
D	1.0×10^{-8}	m^2/h	Tsumura [12] Jain [6]
ϵ	0.24	dimensionless	Weddell [13]
k_{int}	0.18	h^{-1}	Nessler [1] Durbin [4] Jin [7] Maass [9]
k_{pro}	3.85×10^{-4}	h^{-1}	Rich [10]
G_0	2.5×10^3	nM	Wu [14] Antony [2]
k_{ic}	0.6	h^{-1}	estimated
k_{kill}	4.0×10^{-3}	h^{-1}	Simeoni [11]
DAR	4.0	Dimensionless	Fu [5] Lopez de Sa [8]
$EC50$	8.0	nM	estimated
k_{cl}	3.0×10^{-2}	h^{-1}	Simeoni [11]
V_{serum}	3.13	L	Weddell [13]
V_{tight}	58.57	L	Weddell [13]
V_{leaky}	8.93	L	Weddell [13]
V_{lymph}	0.27	L	Weddell [13]
k_1	9.7519	L/h	Weddell [13]
k_2	.156	L/h	Weddell [13]
k_3	97.324	L/h	Weddell [13]
k_4	4.0186	L/h	Weddell [13]
k_5	.128	L/h	Weddell [13]
k_6	80.212	L/h	Weddell [13]
k_7	.355	L/h	Weddell [13]
l_8	.016	h^{-1}	Weddell [13]
l_9	1.0×10^{-4}	h^{-1}	Weddell [13]

REFERENCES

- [1] *The Challenges Facing Antibody-Drug Conjugates for Immuno-Oncology*. <https://oxfordglobal.com/nextgen-biomed/resources/the-challenges-facing-antibody-drug-conjugates-for-immuno-oncology>. Accessed: 2025-02-14.
- [2] A. ANTONY, Y. S. TANG, R. A. KHAN, M. P. BIJU, X. XIAO, L. Q. J., X. L. SUN, H. N. JAYARAM, AND S. P. STABLER, *Translational upregulation of folate receptors is mediated by homocysteine via rna heterogeneous nuclear ribonucleoprotein e1 interactions*, J. Clin. Invest., 113 (2004), <https://doi.org/10.1172/JCI200411548>.
- [3] A. DATTA-MANNAN, H. CHOI, Z. JIN, L. LIU, J. LU, D. J. STOKEL, A. T. MURPHY, K. W. DUNN, M. M. MARTINEZ, AND Y. FENG, *Reducing target binding affinity improves the therapeutic index of anti-met antibody-drug conjugate in tumor bearing animals.*, PLoS ONE, 19 (2024), <https://doi.org/10.1371/journal.pone.0293703>.
- [4] K. R. DURBIN, C. PHIPPS, AND X. LIAO, *Mechanistic modeling of antibody-drug conjugate internalization at the cellular level reveals inefficient processing steps*, Mol Cancer Ther, 17 (2018), <https://doi.org/10.4161/mabs.28965>.
- [5] Z. FU, S. LI, S. HAN, C. SHI, AND Y. ZHANG, *Antibody drug conjugate: the “biological missile” for targeted cancer therapy*, Signal Transduction and Targeted Therapy, 7 (2022), <https://doi.org/10.1038/s41392-022-00947-7>.
- [6] R. K. JAIN, *Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors*, Cancer Research, 50 (1990).
- [7] Y. JIN, M. A. SCHLADETSCH, X. HUANG, M. J. BALUNAS, AND A. J. WIEMER, *Stepping forward in antibody-drug conjugate development*, Pharmacol Ther., 229 (2022), <https://doi.org/10.1016/j.pharmthera.2021.107917>.
- [8] A. LOPEZ DE SA, C. DIAZ-TEJEIRO, E. PYATOS-RACIONERO, C. NIETO-JIMENEZ, L. PANIAGUA-HERRANZ, A. SANVICENTE, E. CALVO, P. PEREZ-SEGURA, V. MORENO, F. MORIS, AND A. OCANA, *Considerations for the design of antibody drug conjugates (adc) for clinical development: lessons learned*, J Hematol Oncol, 16 (2023), <https://doi.org/10.1186/s13045-023-01519-0>.
- [9] K. F. MAASS, C. KULKARNI, A. M. BETTS, AND K. D. WITTRUP, *Determination of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (adc) highlights key parameters for adc design.*, AAPS Journal, 18 (2016), <https://doi.org/10.1208/s12248-016-9892-3>.
- [10] N. E. RICH, B. V. JOHN, N. D. PARIKH, I. ROWE, N. MEHTA, G. KHATRI, S. M. THOMAS, M. ANIS, M. MENDIRATTA-LALA, C. HERNANDEZ, M. ODEWOLE, L. T. SUNDARAM, V. R. KONJETI, S. SHETTY, T. SHAH, H. ZHU, A. C. YOPP, Y. HOSHIDA, F. Y. YAO, J. A. MARRERO, AND A. G. SINGAL, *Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis*, Hepatology, 72 (2020), <https://doi.org/10.1071/CH08240>.
- [11] M. SIMEONI, P. MAGNI, C. CAMMIA, G. DE NICOLAO, V. CROCI, AND E. PESENTI, *Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents*, Cancer Research, 64 (2004).
- [12] R. TSUMUA, S. MANABE, H. TAKASHIMA, Y. KOGA, Y. MASAHIRO, AND Y. MASUMURA, *E influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor*, Journal of Controlled Release, 284 (2018), <https://doi.org/10.1016/j.jconrel.2018.06.016>.
- [13] J. WEDDELL, M. S. CHINEY, S. BHATNAGAR, J. P. GIBBS, AND M. SHEBLEY, *Mechanistic modeling of intra-tumor spatial distribution of antibody-drug conjugates: Insights into dosing strategies in oncology*, Clin Transl Sci, 14 (2021), <https://doi.org/10.1111/cts.12892>.
- [14] R. WU, C. LIANG, J. ZOI, C. LI, Y. YAN, X. HU, AND X. LING, *Detection of membrane receptors on per tumor cell by nonimmobilized cell capillary electrophoresis and a mathematic model*, Talanta, 222 (2020), <https://doi.org/10.1016/j.talanta.2020.121425>.